Association between a cognitive screening test and severe chemotherapy toxicity in older adults with cancer Journal Article


Authors: Jayani, R. V.; Magnuson, A. M.; Sun, C. L.; Ma, H.; Tew, W. P.; Mohile, S. G.; Gajra, A.; Klepin, H. D.; Gross, C. P.; Muss, H. B.; Chapman, A. E.; Katheria, V.; Hurria, A.; Dale, W.
Article Title: Association between a cognitive screening test and severe chemotherapy toxicity in older adults with cancer
Abstract: Introduction: Cognitive impairment (CI) increases chemotherapy toxicity risk with need to understand this association utilizing publicly available short screening tools. We evaluated this utilizing a lower threshold on a short screening tool in older adults with cancer. Materials and methods: We analyzed data from the Cancer and Aging Research Group (CARG) Chemotherapy Toxicity Risk tool (CARG score) development and validation cohorts (n = 703), which recruited adults age ≥ 65 with cancer from academic centers. Cognition was evaluated with the Blessed Orientation-Memory-Concentration test (BOMC). Patients with BOMC score ≥ 11 were excluded. Utilizing cut-points for older adults, we considered moderate BOMC scores (5-10) as potential CI. Logistic regression was used for analysis. Results: Patient baseline characteristics included: mean age 73; 85% white; 63% college or higher education; 250 (36%) potential CI; 385 (55%) severe toxicity. Patients with potential CI were more likely non-white (p ≤ 0.01) and to have high school or lower education (p ≤ 0.01) and high CARG score (p = 0.04). Potential CI was associated with increased severe toxicity risk (OR = 1.54, p ≤ 0.01). After adjusting for CARG score, this association became nonsignificant (OR = 1.35; p = 0.08). Among patients with lower education (n = 258; 36.7%), potential CI remained associated with severe toxicity, even after adjusting for CARG score (OR = 1.87, p = 0.03). Conclusions: Our findings suggest potential cognitive impairment, defined by BOMC score 5–10, in older adults with cancer and lower education is associated with increased severe toxicity risk. Future studies are needed to validate these findings. Healthcare providers should consider cognitive testing before treatment for these vulnerable patients. © 2019
Keywords: cancer chemotherapy; aged; major clinical study; unspecified side effect; antineoplastic agent; breast cancer; lung cancer; urogenital tract cancer; digestive system cancer; cognitive defect; educational status; screening test; university hospital; female genital tract cancer; very elderly; human; male; female; priority journal; article; blessed orientation memory concentration test; cancer and aging research group toxicity risk score; dementia assessment
Journal Title: Journal of Geriatric Oncology
Volume: 11
Issue: 2
ISSN: 1879-4068
Publisher: Elsevier Inc.  
Date Published: 2020-03-01
Start Page: 284
End Page: 289
Language: English
DOI: 10.1016/j.jgo.2019.10.004
PUBMED: 31813840
PROVIDER: scopus
PMCID: PMC7054133
DOI/URL:
Notes: Article -- Export Date: 1 April 2020 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. William P Tew
    226 Tew